Steve M. Sabus - 05 Dec 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Commercial Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
05 Dec 2022
Net transactions value
+$5,596,800
Form type
4
Filing time
05 Dec 2022, 15:41:39 UTC
Previous filing
17 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $5,596,800 +220,000 $25.44 220,000 05 Dec 2022 Common Stock 220,000 $25.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty five percent (25%) of the total number of shares underlying the option shall vest on December 5, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.